The fate of an intravenous dose of tritiated vitamin D 3 was studied in seven normal subjects, four children with vitamin D-resistant rickets, and four adults with a familial history of vitamin D-resistant rickets and persistent hypophosphatemia. An abnormal metabolism of vitamin D in vitamin D-resistant rickets was defined and characterized by a decrease in the plasma fractional turnover rate, a marked increase in plasma water-soluble metabolites, and a relative decrease in the conversion of vitamin D to a polar, biologically active metabolite. Alterations in vitamin D metabolism in the adults with persistent hypophosphatemia were similar but less severe than those of affected children with vitamin D-resistant rickets. It is tentatively concluded that the abnormalities in vitamin D metabolism documented in patients with vitamin D-resistant rickets and familial hypophosphatemia may account for the observed osseous and biochemical changes.
Introduction
Familial (hereditary) vitamin D-resistant rickets in its typical form presents a number of characteristics that tend to set it apart as a single, presumably genetically determined entity (1-3): (a) inheritance as a single-dose effect in the xlinked gene (sex-linked dominance); (b) hypophosphatemia as the most consistent, genetically associated abnormality and often the only abnormality in many affected family members (FamHypo); (c) active rickets or osteomalacia in some family members, which fails to respond to treatment with nutritional doses of vitamins D2 or D8 (VDRR); (d) diminished net tubular reabsorp-tion of inorganic phosphate; (e) decreased gastrointestinal absorption of calcium; and (f) at times, unusual histologic changes in bone and other changes including increased bone density (4) .
Although attempts have been made to base a pathogenetic concept primarily on each one of the three major affected sites, i.e. renal, gastrointestinal, and osseous, no theory dependent on an abnormality intrinsic to one organ system adequately explains the pathological or functional abnormalities in the other two organ systems. Therefore, a unifying concept to explain the underling pathogenesis is still lacking.
Recent studies in two patients with VDRR by DeLuca, Lund, Rosenbloom, and Lobeck reveal a distinct abnormality in the metabolism of radioactive vitamin D, characterized by abnormal amounts of water-soluble vitamin D plasma metabolites 16 hr after vitamin D3-3H injection (5) . The present study, undertaken to evaluate this metabolic abnormality in VDRR, provides further evidence that the metabolism of vitamin D in VDRR patients differs significantly from that observed in normal subjects. 1907
Four children with vitamin D-resistant rickets, four adults with persistent hypophosphatemia, and seven normal healthy volunteers were used for these studies. Three of the four children with vitamin D-resistant rickets had never received vitamin D therapeutically. The fourth (P. W., Table I ) had been treated since age 7 with large doses of vitamin D and for the 8 month period immediately preceding the present study had been receiving 150,000 U of vitamin D per day. Three of the hypophosphatemic adults were of the same pedigree as the affected children (D. B. and L. B., J. E. and L. E., G. D. and L. D., Table I ). The fourth adult hypophosphatemic patient (T. C., Table I ) gave a history of severely bowed legs since childhood but had never received vitamin D therapeutically. She also had a strong family history of VDRR. The vitamin D-resistant subjects were selected on the basis of abnormal elevations in serum alkaline phosphatase, hypophosphatemia (Table I) , and roentgenograms consistent with active rickets. The three adult relatives of the affected children (L. D., L. E., and L. B., Table I ) were selected because of persistent hypophosphatemia and a family history of VDRR. All subj ects were studied in ambulatory states during periods of hospitalization on a Clinical Research Center Ward.
1 hr before breakfast after a 12-15 hr overnight fast, 5-8 ,uc of randomly labeled vitamin D3-'H (Ds-'H) with a specific activity of 72 Asc/mg, prepared and purified by the method of DeLuca et al. (6) , was dissolved in 0.5-1.0 ml of absolute ethanol and administered intravenously During the first day, cumulative 6-hr urine collections were made. Thereafter, urine was collected during 8-hr periods for the remainder of the study. All urine collections were refrigerated and subsequently lyophilized. Cumulative fecal collections were made during the 48 hr study period; these were homogenized with water in a Waring Blendor and aliquots were lyophilized. All fecal collections were initiated and terminated with enemata to ensure their complete recovery.
Determination of total 'H in biological samples. 1-2-ml samples of whole plasma, lyophilized feces, and urine were combusted according to the procedure of Kelly et al. (7), utilizing a Thomas Ogg Safety Igniter (A. H. Thomas Co., Philadelphia, Pa.).
The resulting 'H water vapor was frozen on the bottom of a 2 liter Erlenmeyer flask and placed in a dry ice-acetone bath for 45 min. 20 ml of liquid scintillation counting solution A was added and the flask was allowed to stand in the crushed ice bath for 45 min. Then 18 ml of the solution was withdrawn and assayed for radioactivity. The efficiency of the tritium counting, which was strongly dependent on the amount of water vapor present in the sample, varied between 7 and 15%o. Recoveries of 3H-vitamin D3 added to nonradioactive samples of plasma, urine, and feces ranged between 96 and 102%.
Extraction of radioactivity. The lipid-soluble radioactivity present in plasma, urine, and feces was extracted by the procedure of Bligh and Dyer (8) as previously described (9) . After filtration to remove the denatured protein, the phases were allowed to separate overnight at 120 C. The denatured protein was found to contain little or no tritium after this extraction procedure. The aqueous-methanol layer was routinely reextracted three times with additional volumes of chloroform and these extracts were combined and concentrated by evaporation with nitrogen gas. 2 ml of the aqueous layer was added to counting solution B and assayed for radioactivity. 1-2-ml aliquots of chloroform-soluble radioactivity were added to counting solution C and also assayed for radioactivity.
Chromatography. Thin-layer chromatography apparatus and Cab-O-Sil silica gel G (Research Specialties Co., Richmond, Calif.) were used to prepare the thinlayer silicic plates. 10 jig of crystalline, nonradioactive vitamin Da were placed at the origin on each side of the plate as a marker. Aliquots of the chloroform-soluble extract were then applied across the origin of the plate between the marker vitamin D spots. The plates were then chromatographed in a solvent of 10%o acetone in n-hexane (v/v) as previously described (6) . After drying, the plates were sprayed with 0.20% KMnO4 in 1% Na2CO3 to locate the marker vitamin D. The radioactivity was then located by scraping off successive 0.5 20 Silicic acid column chromatography of chloroform extracts of 24-hr plasma and cumulative fecal and urine specimens was carried out essentially as described previously (10) . After extraction by a modification of the method of Bligh and Dyer (8) , the chloroform phase of plasma, urine, and fecal specimens was evaporated to dryness under vacuum with a flash evaporator and the residue redissolved in hexane. The hexane phase was then applied to silicic acid columns, 58 X 1.5 cm, and chromatographed with a hyperbolic gradient of diethyl ether in petroleum ether, whereupon serial collections of 10 ml were made. The collected fractions were evaporated; 20 ml of counting solution C was added and radioactivity measured in a liquid scintillation counter.
Measurement of radioactivity. 
Results

Metabolic fate of plasma D3-8H radioactivity
The plasma disappearance of D8-8H in normal, VDRR, and FamHypo subjects ( Fig. 1) The material in peak 3 has been previously idenfied as unaltered vitamin D5 (9, 12) . The polar substance in peak 4 previously isolated from both rat (9, 10) and human (10, 12) plasma has been shown to possess potent biological activity (12, 13) . Peak 1, as noted in Table III , previously identified in humans by Avioli, Lund, DeLuca, and McDonald as a vitamin D ester (9, 12) , was characteristically absent from the plasma of normal and FamHypo subjects. However, in two of the four patients with VDRR, peak 1 represented 3-4%o fractionated radioactivity. Subsequently, 24-hr plasma extracts from these same subjects (D. B. and J. E., Table III ) were saponified by refluxing under nitrogen for 30 min in 10% KOH in methanol (v/v), and the saponified material was extracted with small volumes of diethyl ether. The extracts were combined and dried over anhydrous CaSO4. The ether evaporated and the residue was dissolved in hexane. * The chloroform extracts of plasma obtained 24 hr after an intravenous dose of vitamin D3-3H were chromatographed on a 24 g silicic acid column with a gradient of diethyl ether in petroleum ether (9, 10). 10-ml fractions were collected. Peak 1 represents fractions 10-14; peak 2, fractions 17-23; peak 3, fractions 24-30; peak 4, fractions 59-65. VITAMIN 
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The hexane extract was then rechromatographed on silicic acid columns in the identical hyperbolic gradient system described earlier (10). As illustrated for J. E. in Fig. 2 , saponification resulted in a disappearance of peak 1 in the VDRR subjects and an increase in the percentage of the recoverable radioactivity in peak 3.
In both normal and VDRR subjects saponification also induced a decrease in the amount of chloroform-soluble radioactivity that chromatographed as peak 4 (Figs. 2 and 3) . Similar observations have also been made after chromatography of saponified plasma samples from animals injected with D3-3H (9) . Whereas 35%o of the radioactivity recovered during the chromatographic procedure was normally present in peak 4, an average of 9 and 19%o, respectively, of chloroform-soluble, 24 hr plasma radioactivity was identified as peak 4 (12) and animals (9) indicated that significant metabolism of D3-3H normally obtains at 24 hr after its administration, only 24-hr plasma samples from normal, VDRR, and FamHypo individuals were subjected to more definitive column chromatographic separation procedures. The observed decrease in 24 hr plasma peak 4 content in VDRR and FamHypo subjects and the increase in D,-3H plasma half-time in these same individuals (Fig. 1) are consistent with an abnormal conversion of D3-3H to its more polar peak 4 metabolite. The abnormally low concentration of D3-3H polar metabolites noted on thin-layer chromatograms during the entire 48 hr study lends support to this hypothesis. Heretofore, relatively little information was available concerning the metabolism of vitamin D in man. Recent studies in human subjects from this laboratory have demonstrated the role of the hepato-biliary tract in the metabolism of vitamin D (12) . Biologically active metabolites have also been isolated from plasma, bone, intestine, and kidney in rats (9, 10) and from plasma in man (5, 9, 12) . Several investigators have often cited the paradox of markedly elevated blood levels of vitamin D during therapy of VDRR with "inherent resistance" to its action and have postulated a defect in the metabolism of vitamin D to account for the discrepancy (14, 15) . In the past, experimental evidence to verify this hypothesis was absent. Recently DeLuca, Lund, Rosenbloom, and Lobeck administered D3-8H to two control subjects, an 18 yr old male with VDRR and his 42 yr old mother with a childhood history of VDRR (5) . 16 hr after the D5-3H injection, these investigators found abnormally elevated concentrations of total plasma ial2 radioactivity and an increase in plasma aqueous Da-8H metabolites up to values 20 times normal in both affected individuals.
In 1965 Scott et al. administered radioactive D3 orally to 10 patients with vitamin D-resistant rickets and noted "significantly lower removal rates of plasma D3-3H" (16) . These investigators also commented on a decrease in the intestinal absorption of D3-3H in the VDRR subjects, as reflected by a decrease in lipid-soluble radioactivity after the oral D3-8H dose. As noted in the present report, the plasma lipid-soluble radioactivity in subjects with VDRR is lower than normal after intravenous D8-8H. These latter observations of Scott et al. most likely represent the abnormal metabolism of vitamin D resulting in abnormally low lipid-soluble plasma radioactivity initially cited by DeLuca et al. (5), and confirmed in the present report, rather than a malabsorption of vitamin D. Since blood levels of vitamin D (measured by bioassay) have been shown to be normal in VDRR before treatment and markedly elevated after therapeutic oral doses (14, 17, 18) , and since parenteral vitamin D therapy has reportedly failed to cure VDRR (19) (20) (21) , any abnormality in the intestinal absorption of vitamin D in VDRR seems remote.
As noted in Table IV , the increase in plasma water-soluble metabolites noted in VDRR was also associated with an increase in water-soluble urine radioactivity. Normally, 10% of the urine radioactivity can be accounted for by water-soluble glucuronide conjugates and an additional 16% by water-soluble, acid-labile conjugates (12) . When the water-soluble urine extracts of VDRR subjects were subjected to B-glucuronidase and acid hydrolysis according to previously described techniques (12) , the concentrations of glucuronide and acid-labile substances were within normal limits. Inasmuch as the liver can apparently conjugate vitamin D and its metabolites normally in VDRR, the observed defect in D3-8H metabolism is probably extrahepatic.
Of the three major functional and/or morphological abnormalities associated with VDRR, in kidneys, gastrointestinal tract, and bone, the findings of this study and of other recent work may be directly related to two abnormalities. Firstly, with regard to the well-documented subnormal gastro-intestinal absorption of calcium in VDRR (3, 14, (22) (23) (24) (25) , the material isolated as peak 4 in the present study, and found to be significantly decreased in amount in three of the four patients with VDRR 24 hr after D3-8H infusion (Table  III) , has recently been shown to be twice as effective as vitamin D in stimulating the intestinal transport of calcium (9, 13) . Thus, a relative deficiency of the active peak 4 metabolite in patients with VDRR could possibly result in defective calcium absorption.
Secondly, it is possible that the decrease in vitamin D turnover in VDRR and, in particular, the decreased amounts of peak 4 metabolite are related to the bony abnormalities found in VDRR. Radioautographs of bone obtained after radioactive vitamin D injection demonstrate localized radioactivity in'the cytoplasm of chondrocytes in the proliferating cartilage zone of growing bone (26) ; experiments by Lund and DeLuca (9, 13) reveal that the peak 4 metabolite represents the majority of radioactivity in rat bone while vitamin D, itself, is present in only small amounts. Furthermore, the peak 4 metabolite has been shown to be as biologically active as the parent vitamin in curing rickets in rats (9, 12) .
That vitamin D (or its metabolites) is directly involved in bone metabolism, in addition to its effects on the availability of calcium, has long been suggested. Vitamin D deficiency in dogs (27) and rats (28) results in trabecular changes and increased noncalcium content of the shafts of long bones that are not directly related to the amounts of absorbed calcium and phosphate. Moreover, recent experiments by Au and Bartter (29) and Cruess and Clark (30) indicate that the vitamin D has a direct effect on bone metabolism independent of its known effects on the intestinal absorption of calcium. In bone from patients with VDRR, in addition to the typical rachitic changes, other abnormalities not found in vitamin D-deficiency rickets have been described. These include an irregular mosaic formation of the haversian system and trabecular (31) (32) (33) "halos" of low-density bone, together with a "dynamic" abnormality in osteoblastic development (4, 34) , and abnormal metabolism of chondroitin sulfate and alkaline phosphatase (35) . It (Tables II  and IV ). The identity of these water-soluble metabolites has yet to be determined. To date, essentially no antirachitic vitamin D-like biological activity has been detected in any of the watersoluble Di-8H metabolites, which suggests that the metabolites most probably represent degradation products of vitamin D (9) . It is possible that increased amounts of these steroids in the glomerular filtrate, and thus within the renal tubule, could act directly to decrease net phosphate reabsorption since three other -steroids, cortisone, hydrocortisone, and diethylstilbesterol, have been shown to have such an effect (38-40).
Other aspects of the present observations still remain to be clarified. The Table IV is also presently obscure. Associated increments in fecal material which migrates with the same Rf as vitamin D8 is also of note since this material lacks-biological activity (9) . It may represent endogenously secreted degradation products of vitamin D with relatively minor structural alterations that are not readily separated from the parent vitamin by the chromatographic procedures used in the present study; or the increments may be the result of bacterial decomposition of vitamin D metabolites (26) .
